Sigma® Life Science Announces Scientific Advisory Board to drive ADME/Tox program
Sigma® Life Science Announces Scientific Advisory Board to drive ADME/Tox program Board to Provide Counsel on New Solutions for Pre-clinical Testing with Sigma’s CompoZr® Zinc Finger Nuclease (ZFN) Technology
The role of the SAB will be to identify emerging trends in pre-clinical pharmaceutical testing, in an effort to enable Sigma Life Science to meet the changing needs of the ADME/Tox market. The board is comprised of pre-eminent scientists and key opinion leaders from both academia and industry, including:
Dr. J. Scott Daniels, Vanderbilt University Medical Center
Dr. Judith K. Jones, The Degge Group, Ltd.
Dr. Curtis Klaassen, University of Kansas Medical Center
Dr. Russell Thomas, The Hamner Institutes for Health Sciences
“The expertise of the ADME/Tox SAB, together with the advanced genome editing capabilities of CompoZr ZFNs, can put Sigma Life Science at the forefront of development in this area,” said Dr. Daniels. “Application of these genomic tools within the ADME/Tox sector should help to improve the accuracy and biological relevance of ADME assays and provide toxicologists with better predictive tools for pre-clinical testing, ultimately reducing the attrition of drug candidates in subsequent clinical trials.”
The first products to be developed under this initiative – due for release later this year – are designed to address the U.S. Food and Drug Administration and European Medicines Agency requirements for in vitro testing of candidate drug interactions with known efflux transporter proteins. These knockout (KO) cell lines are intended to allow researchers to investigate drug¬transporter interactions, providing more biologically relevant data to avoid costly failures during subsequent clinical testing.
Dr Supriya Shivakumar, Global Commercial Marketing Manager for Functional Genomics at Sigma Life Science added, “Our CompoZr ZFN technology offers precise, complete knockout of the transporter gene of interest, allowing direct comparison between parent and KO cell lines to screen for potential drug-transporter interactions. This strategy offers highly predictable and reproducible testing, and eliminates the off-target effects associated with many of the molecular tools currently used for these screens.”
Formation of the ADME/Tox SAB is the first step in Sigma Life Science’s strategic program to develop novel assays for this market. In addition to creating a range of novel cell-based assays in-house, this enabling technology of Sigma-Aldrich®
Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as “in an effort", "expected,” "are intended," "offers," "can," "should'" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the ADME/Tox products described herein will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with ADME/Tox products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company’s leadership in innovative biological products and services for the global life science market and offers an array of biologically-
Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.